朱建华

• 1:浙江大学医学院附属第一医院心内科

摘要(Abstract)：

<正>自从2012年欧洲第5版心血管疾病预防指南(以下简称《2012年指南》)颁布以来,关于心血管疾病预防的新研究证据更加充实[1]。因此,2016年5月欧洲心脏病学会(ESC)联合其他9个心血管疾病预防学会共同发布了第6版《2016年欧洲心血管疾病预防的临床实践指南》(以下简称《2016年指南》)[2]。与《2012年指南》相比,《2016年指南》更

关键词(KeyWords)： 心血管疾病;SCORE评分;指南解读

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 朱建华

参考文献(References)：

• [1]Perk J,De Backer G,Gohlke H,et al.European Guidelines on cardiovascular disease prevention in clinical practice(version2012).The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice(constituted by representatives of nine societies and by invited experts).Eur Heart J,2012,33(13):1635-1701.
• [2]Jiménez Navarro MF.Comments on the 2016 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice.Rev Esp Cardiol(Engl Ed),2016,69(10):894-899.
• [3]Andrus B,Lacaille D.2013 ACC/AHA guideline on the assessment of cardiovascular risk.J Am Coll Cardiol,2014,63(25 Pt A):2886.
• [4]Conroy RM,Py9rlK,Fitzgerald AP,et al.Estimation of tenyear risk of fatal cardiovascular disease in Europe:the SCORE project.Eur Heart J,2003,24(11):987-1003.
• [5]中国医师协会心血管分会.心血管疾病戒烟干预中国专家共识.中华内科杂志,2012,51(2):161-167.
• [6]中华人民共和国国家卫生和计划生育委员会.中国临床戒烟指南(2015年版).中华健康管理学杂志,2016,10(2):88-95.
• [7]Catapano AL,Graham I,De Backer G,et al.2016 ESC/EAS Guidelines for the management of dyslipidaemias:The task force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and European Atherosclerosis Society(EAS)developed with the special contribution of the European Assocciation for Cardiovascular Prevention&Rehabilitation(EACPR).Eur Heart J,2016.[Epub ahead of print]
• [8]Rydén L,Grant PJ,Anker SD,et al.ESC Guidelines on diabetes,pre-diabetes,and cardiovascular diseases developed in collaboration with the EASD:the Task Force on diabetes,prediabetes,and cardiovascular diseases of the European Society of Cardiology(ESC)and developed in collaboration with the European Association for the Study of Diabetes(EASD).Eur Heart J,2013,34(39):3035-3087.
• [9]James PA,Oparil S,Carter BL,et al.2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee(JNC 8).Jama,2014,311(5):507-520.
• [10]Weber MA,Schiffrin EL,White WB,et al.Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension.J Hypertens,2014,32(1):3-15.
• [11]Wright JT Jr,Williamson JD,Whelton PK,et al.A randomized trial of intensive versus standard blood-pressure control.N Engl J Med,2015,373(22):2103-2116.
• [12]Levine GN,Bates ER,Bittl JA,et al.2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease:A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines:An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention,2011 ACCF/AHA guideline for coronary artery bypass graft surgery,2012ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease,2013 ACCF/AHA guideline for the management of STelevation myocardial infarction,2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes,and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery.Circulation,2016,134(10):e123-e155.
• [13]Bonaca MP,Bhatt DL,Cohen M,et al.Long-term use of ticagrelor in patients with prior myocardial infarction.N Engl J Med,2015,372(19):1791-1800.
• [14]Mauri L,Kereiakes DJ,Yeh RW,et al.Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.N Engl J Med,2014,371(23):2155-2166.
• [15]Marso SP,Daniels GH,Brown-Frandsen K,et al.Liraglutide and cardiovascular outcomes in type 2 diabetes.N Engl J Med,2016,375(4):311-322.
• [16]Zinman B,Wanner C,Lachin JM,et al.Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes.N Engl J Med,2015,373(22):2117-2128.
• [17]Yusuf S,Lonn E,Pais P,et al.Blood-pressure and cholesterol lowering in persons without cardiovascular disease.N Engl J Med,2016,374(21):2032-2043.